EUVIMEDEUVIMED entdecken
Multizentrische Studie

Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers

Cristina Smolenschi, Jean-Frédéric Blanc, Anna Lancry, Elodie Klajer, Audrey Debaillon-Vesque, Jean Marie Vantelon, Alice Boileve, Marine Valery, Antoine Hollebecque, Michel Ducreux, Marie Decraecker

European Journal of Cancer · 2025-06 · 222 · 115432

DOI: 10.1016/j.ejca.2025.115432 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2025-06. Verfasst von Cristina Smolenschi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Gustave Roussy, Villejuif, France; Drug Development Department, Gustave Roussy, Villejuif, France. Electronic address: c…. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Biliary Tract Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesBiliary Tract NeoplasmsAntibodies, Monoclonal, HumanizedHumansMiddle AgedFemaleAgedMaleRetrospective StudiesFranceTreatment OutcomeAntibodies, Bispecific

Stichwörter der Autor:innen

CholangiocarcinomaHER amplificationTargetable treatment

Substanzen

Erb-b2 Receptor Tyrosine KinasesAntibodies, Monoclonal, HumanizedAntibodies, BispecificERBB2 protein, humanzanidatamab

Autor:innen und Institutionen

  • Medical Oncology Department, Gustave Roussy, Villejuif, France; Drug Development Department, Gustave Roussy, Villejuif, France. Electronic address: cristina.smolenschi@gustaveroussy.fr.
  • Oncology Unit, Hôpital Haut Lévêque, CIC 1401, Bordeaux University Hospital, Pessac 33604, France.
  • Oncology Unit, Hôpital de la Timone, Marseille, France.
  • Oncology Unit, Hospital of Besançon, Besançon, France.
  • Oncology Unit,Clinique d'Occitanie, Muret, France.
  • Medical Oncology Department, Gustave Roussy, Villejuif, France.

Zitieren

APA

Smolenschi, C., Blanc, J. F., Lancry, A., Klajer, E., Debaillon-Vesque, A., Vantelon, J. M., Boileve, A., Valery, M., Hollebecque, A., Ducreux, M., & Decraecker, M. (2025). Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers. European Journal of Cancer, 222, 115432. https://doi.org/10.1016/j.ejca.2025.115432

Vancouver

Smolenschi C, Blanc JF, Lancry A, Klajer E, Debaillon-Vesque A, Vantelon JM, et al. Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers. European Journal of Cancer. 2025;222:115432. doi:10.1016/j.ejca.2025.115432

BibTeX
@article{Smolenschi2025,
  author = {Smolenschi, Cristina and Blanc, Jean-Frédéric and Lancry, Anna and Klajer, Elodie and Debaillon-Vesque, Audrey and Vantelon, Jean Marie and Boileve, Alice and Valery, Marine and Hollebecque, Antoine and Ducreux, Michel and Decraecker, Marie},
  title = {Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers},
  journal = {European Journal of Cancer},
  year = {2025},
  volume = {222},
  pages = {115432},
  doi = {10.1016/j.ejca.2025.115432}
}
Kostenlos starten →